Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma

Annals of Surgical Oncology

Volumn 18, Issue 10, 2011, Pages 2841-2850

  Yonemori, Kan ^a   Tsuta, Koji ^a   Ando, Masashi ^a   Hirakawa, Akihiro ^b   Hatanaka, Yutaka ^c   Matsuno, Yoshihiro ^c   Chuman, Hirokazu ^a   Yamazaki, Naoya ^a   Fujiwara, Yasuhiro ^a   Hasegawa, Tadashi ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMANGIOSARCOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 80052771345     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1640-4     Document Type: Article

References (31)

1. N Naka M Ohsawa Y Tomita, et al. 1996 Prognostic factors in angiosarcoma: multivariate analysis of 55 cases J Surg Oncol. 61 170 176 8637202 10.1002/(SICI)1096-9098(199603)61:3<170::AID-JSO2>3.0.CO;2-8 1:STN:280:DyaK283gslOhtw%3D%3D (Pubitemid 26097066)
2. CN Otis R Peschel C McKhann MJ Merino PH Duray 1986 The rapid onset of cutaneous angiosarcoma after radiotherapy for breast carcinoma Cancer. 57 2130 2134 3008975 10.1002/1097-0142(19860601)57:11<2130::AID-CNCR2820571108>3. 0.CO;2-4 1:STN:280:DyaL287ovFCjuw%3D%3D (Pubitemid 16121744)
3. JA Benda AS Al-Jurf AB Benson III 1987 Angiosarcoma of the breast following segmental mastectomy complicated by lymphedema Am J Clin Pathol. 87 651 655 3034052 1:STN:280:DyaL2s3gvF2jug%3D%3D (Pubitemid 17076609)
4. J Fayette E Martin S Piperno-Neumann, et al. 2007 Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases Ann Oncol. 18 2030 2036 17974557 10.1093/annonc/mdm381 1:STN:280:DC%2BD2sjkt1ektQ%3D%3D (Pubitemid 350286245)
5. G Lahat AR Dhuka H Hallevi, et al. 2010 Angiosarcoma: clinical and molecular insights Ann Surg. 251 1098 1106 20485141 10.1097/SLA.0b013e3181dbb75a
6. J Verweij LH Baker 2010 Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations Eur J Cancer. 46 863 868 20138507 10.1016/j.ejca.2010.01.016 1:CAS:528:DC%2BC3cXivFGmsLs%3D
7. JL Ordóñez AS Martins D Osuna J Madoz-Gurpide E de Alava 2008 Targeting sarcomas: therapeutic targets and their rational Semin Diagn Pathol. 25 304 316 19013896 10.1053/j.semdp.2008.07.005
8. C Behrens HY Lin JJ Lee, et al. 2008 Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer Clin Can Res. 14 6014 6022 10.1158/1078-0432. CCR-08-0167 1:CAS:528:DC%2BD1cXhtF2nurrO
9. T Shet A Malaviya M Nadkarni, et al. 2006 Primary angiosarcoma of the breast: observations in Asian Indian women J Surg Oncol. 94 368 374 16967461 10.1002/jso.20593 (Pubitemid 44465339)
10. JL Hornick CD Fletcher 2002 Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution Am J Clin Pathol. 117 188 193 11865845 10.1309/LX9U-F7P0-UWDH-8Y6R (Pubitemid 34823657)
11. R Komdeur HJ Hoekstra WM Molenaar, et al. 2003 Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target Clin Cancer Res. 9 2926 2932 12912938 1:CAS:528:DC%2BD3sXmtF2iu7g%3D (Pubitemid 36993251)
12. M Miettinen M Sarlomo-Rikala J Lasota 2000 KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit Mod Pathol. 13 536 541 10824925 10.1038/modpathol.3880093 1:STN:280:DC%2BD3c3otlSltQ%3D%3D (Pubitemid 30332105)
13. C Palman DF Bowen-Pope JJ Brooks 1992 Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors Lab Invest. 66 108 115 1309926 1:STN:280:DyaK387hsVCqsw%3D%3D
14. E Itakura H Yamamoto Y Oda, et al. 2008 Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas J Surg Oncol. 97 74 81 18041747 10.1002/jso.20766
15. W Tokuyama T Mikami M Masuzawa I Okayasu 2010 Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face Hum Pathol. 41 407 414 19913279 10.1016/j.humpath.2009.08.021 1:CAS:528:DC%2BC3cXitV2ktLY%3D
16. E Stacher U Gruber-Mösenbacher I Halbwedl, et al. 2009 The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer. 65 49 55 19100646 10.1016/j.lungcan.2008.10.031
17. M Hashimoto M Ohsawa A Ohnishi, et al. 1995 Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma Lab Invest. 73 859 863 8558848 1:STN:280:DyaK287gvFWhtg%3D%3D (Pubitemid 26002346)
18. TA Partanen K Alitalo M Miettinen 1999 Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors Cancer. 86 2606 2612 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID- CNCR31>3.0.CO;2-E (Pubitemid 30010384)
19. AL Folpe T Veikkola R Valtola SW Weiss 2000 Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas Mod Pathol. 13 180 185 10697276 10.1038/modpathol.3880033 1:STN:280:DC%2BD3c7mtVenuw%3D%3D (Pubitemid 30109106)
20. S Ghosh CA Sullivan MP Zerkowski, et al. 2008 High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer Hum Pathol. 39 1835 1843 18715621 10.1016/j.humpath.2008.06.004 1:CAS:528:DC%2BD1cXhtlyltbzK
21. NT Okita Y Yamada D Takahari, et al. 2009 Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer Jpn J Clin Oncol. 39 595 600 19535387 10.1093/jjco/hyp066
22. E Carrillo de Santa Pau FC Arias E Caso Peláez, et al. 2009 Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer Cancer. 115 1701 1712 19197998 10.1002/cncr.24193
23. Y Amo M Masuzawa Y Hamada K Katsuoka 2004 Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients Br J Dermatol. 150 160 161 14746640 10.1111/j.1365-2133.2004.05751.x 1:CAS:528: DC%2BD2cXitVKhuro%3D (Pubitemid 38234029)
24. T Kubo S Piperdi J Rosenblum CR Antonescu, et al. 2008 Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma Cancer. 112 2119 2129 18338812 10.1002/cncr.23437 1:CAS:528:DC%2BD1cXmt1Cns7w%3D (Pubitemid 351628620)
25. A Uren MS Merchant CJ Sun, et al. 2003 Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells Oncogene. 22 2334 2342 12700668 10.1038/sj.onc.1206330 1:STN:280:DC%2BD3s7ot1Smtw%3D%3D (Pubitemid 36566788)
26. I Sulzbacher P Birner K Trieb M Muhlbauer S Lang A Chott 2001 Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome Am J Surg Pathol. 25 1520 1527 11717542 10.1097/00000478-200112000-00008 1:STN:280:DC%2BD3MnntFSlsQ%3D%3D (Pubitemid 33096967)
27. N Penel BN Bui JO Bay D Cupissol, et al. 2008 Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study J Clin Oncol. 26 5269 5274 18809609 10.1200/JCO.2008.17.3146 1:CAS:528:DC%2BD1cXhsVyqsrbJ
28. D Belotti V Vergani T Drudis, et al. 1996 The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res. 2 1843 1849 9816139 1:CAS:528:DyaK28Xnt1SitLo%3D (Pubitemid 26384151)
29. RG Maki DR D'Adamo ML Keohan, et al. 2009 Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol. 27 3133 3140 19451436 10.1200/JCO.2008.20.4495 1:CAS:528:DC%2BD1MXhtFWitb3J
30. R Kumar MC Crouthamel DH Rominger, et al. 2009 Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer. 101 1717 1723 19844230 10.1038/sj.bjc.6605366 1:CAS:528:DC%2BD1MXhtl2hs7rL
31. CR Antonescu A Yoshida T Guo, et al. 2009 KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors Cancer Res. 69 7175 7179 19723655 10.1158/0008-5472.CAN-09-2068 1:CAS:528:DC%2BD1MXhtFaku7zL